Piramal Pharma Limited releases unaudited results for quarter ended 30 September 2026
Piramal Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Consolidated revenue from operations ₹2,617.06 crore for quarter ended 30 September 2026
- Consolidated net profit after tax ₹5.03 crore, against a loss of ₹99.22 crore for quarter ended 30 September 2025
- Statutory auditor Suresh Surana & Associates LLP issued limited review reports; board approved results on 27 October 2026
Why it's rated major development: the year-on-year change is 100% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 27Th October, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other acquisition / merger filings this fortnight
- Fine Organic Industries Ltd announces Q2 and H1 FY27 financial results and acquisitions
- Lloyds Metals and Energy Limited announces Q2 FY 2026-27 results and approves investments
- Kotak Mahindra Bank receives CCI approval for Deutsche Bank India business acquisition
- Endurance Technologies reports Q2 and H1 FY27 financial results with growth
- Prestige Estates Projects acquires 100% of Gloind Vintage Infra via PRVL
- Systematic Industries approves half-year results and allots 14,57,400 preferential shares
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.